Ionis Pharma's CEO Just Appeared in a $4.03 Million Sell Filing
Ionis CEO Brett Monia exercised 50,000 options at $56.78 and sold at $80.59 under a December 2025 10b5-1 plan. 245,571 direct shares and 99,872 remaining options retained.
π΄ Insider Activity Score: 96/100
Brett P. Monia, CEO of Ionis Pharmaceuticals, filed a Form 4 on June 26, 2026 disclosing the exercise of 50,000 non-qualified stock options at a $56.78 strike price and the immediate open-market sale of the resulting shares at a volume-weighted average of $80.59 for approximately $4,029,500 β governed by a Rule 10b5-1 plan adopted on December 8, 2025. Following the distribution, Monia retains 245,571 direct common shares and 99,872 remaining long-term option contracts. The December plan ran the exercise-and-sale. The $56.78 strike is the compensation vintage. The 245,571 direct shares plus 99,872 remaining options are the CEO's actual RNA medicine platform alignment.
The December 8, 2025 Plan and the $56.78 Vintage
The plan adoption date of December 8, 2025 β approximately six months before the June 26 execution β places the CEO's distribution decision entirely outside the current biotech sector momentum that produced the $80.59 execution price.
Options struck at $56.78 represent grants issued when Ionis traded near that level β the specific compensation period before the RNA medicine platform's current premium valuation cycle. The $23.81 per-share spread between the $56.78 strike and the $80.59 execution price β approximately $1.19 million in pre-tax compensation gain across 50,000 shares β is the accumulated appreciation that the plan collected when the December calendar triggered in June.
The cash-neutral character of this exercise deserves acknowledgment: the $4,029,500 in gross proceeds substantially exceeds the $2,839,000 exercise cost at $56.78, delivering the full spread as realized compensation income rather than a precisely calibrated cost-recovery event. The plan exercised the full 50,000-option block and sold the resulting shares entirely β the standard full-block exercise-and-flip that this series has documented across expiration-window and plan-governed option conversions.
The 99,872 Remaining Options: Forward Compensation Pipeline
The 99,872 remaining long-term option contracts represent the forward compensation alignment that extends Monia's financial incentive horizon beyond the current plan's June execution β a pipeline of unexercised options whose future value is entirely dependent on whether Ionis's RNA medicine platform continues to appreciate from the $80.59 level.
The CEO retaining 99,872 options after exercising 50,000 through the December plan confirms the plan is not exhausting the compensation pipeline. It is executing a defined tranche while leaving the majority of the option structure in place β the forward options representing the specific long-term compensation alignment that makes the plan's current exercise-and-flip analytically bounded rather than structurally significant.
The 245,571 Direct Share Foundation
The 245,571 direct common shares retained at $80.59 β worth approximately $19.8 million β represent the CEO's unhedged personal equity commitment to Ionis's antisense oligonucleotide and RNA medicine platform. Combined with the 99,872 remaining option contracts, the total equity-linked exposure is substantially larger than the $4.03 million distributed through the December plan's June output.
Ionis operates the world's leading RNA-targeted medicine platform β antisense oligonucleotide therapies addressing neurological, cardiovascular, and rare disease conditions whose clinical and commercial validation has driven the biotech sector premium that delivered $80.59 to the December plan's $56.78 strike options.
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. is a pioneer in RNA-targeted medicine whose antisense oligonucleotide platform has produced multiple approved therapies and a deep clinical pipeline across neurology, cardiology, and rare diseases. CEO Brett P. Monia retains 245,571 direct common shares worth approximately $19.8 million and 99,872 remaining long-term option contracts following the December 8, 2025 Rule 10b5-1 plan's exercise-and-sale of 50,000 options at the $56.78 strike. Ionis Pharmaceuticals trades on the Nasdaq under the ticker IONS.
How to Think About This
Monia's December-plan option exercise scores 96/100 β the alarm-management calibration for a biotech CEO's $4.03 million exercise-and-flip at a leading RNA medicine platform, with the December adoption date providing six months of temporal insulation, the $56.78 vintage contextualizing the mechanism, and the 245,571 direct shares plus 99,872 remaining options confirming the foundational platform alignment is intact.
The plan exercised 50,000 options. The 99,872 remaining option contracts and 245,571 direct shares are backing the RNA medicine platform from the $80.59 level.